[Status of novel bone-targeting SERMs in development].
Ohta
Hiroaki
H
Department of Obstetrics and Gynecology, Tokyo Women' s Medical University.
D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000378:metabolism; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D007211:Indoles / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000517:prevention & control; D010880:Piperidines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D011759:Pyrrolidines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D011960:Receptors, Estrogen / Q000378:metabolism; D012106:Research; D020845:Selective Estrogen Receptor Modulators / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D013764:Tetrahydronaphthalenes / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D013876:Thiophenes / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use
D007211:Indoles; D010880:Piperidines; D011759:Pyrrolidines; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; C111332:Lasofoxifene; C115121:LY 353381; C447119:bazedoxifene